Recent safety findings from the U.S. Food and Drug Administration have brought renewed attention to potential risks linked with Tavneos (avacopan), a medication used to treat a rare autoimmune condition. The agency has identified serious cases of drug induced liver injury, including some fatal outcomes, prompting updated guidance for both healthcare professionals and patients.
Tavneos, also known by its generic name avacopan, received approval in October 2021 as a treatment for adults with severe active anti neutrophil cytoplasmic autoantibody associated vasculitis, often shortened to ANCA associated vasculitis. This group of rare diseases causes inflammation in small to medium sized blood vessels, potentially leading to organ damage.
The medication is typically used alongside glucocorticoids and other standard therapies. While it has provided an alternative approach for managing inflammation, it does not replace the need for glucocorticoids entirely.
The FDA has reported new postmarketing safety data indicating a link between Tavneos and serious liver complications. These include cases of drug induced liver injury, commonly referred to as DILI, as well as a rare but severe condition known as vanishing bile duct syndrome.
Vanishing bile duct syndrome involves the progressive destruction of bile ducts in the liver. This can disrupt bile flow and lead to long term or permanent liver damage. Symptoms may include jaundice, fatigue, itching, and abdominal discomfort.
According to the FDA’s review, 76 cases of liver injury were identified with reasonable evidence suggesting a connection to avacopan use. Of these, 74 cases resulted in serious outcomes such as hospitalization or death. Eight of the reported cases were fatal.
Among these reports, seven cases were confirmed to involve vanishing bile duct syndrome. All seven required hospitalization, and three resulted in death. These findings highlight a concerning safety signal that was not fully recognized during earlier clinical trials.
The FDA analysis found that liver injury typically developed within a median of 46 days after starting treatment. However, onset ranged from as early as 22 days to as late as 140 days.
Most cases showed a cholestatic or mixed pattern of liver injury. This type is often associated with elevated levels of alkaline phosphatase and bilirubin, indicating impaired bile flow. In some instances, a hepatocellular pattern was observed, involving direct injury to liver cells.
Interestingly, the majority of reported cases originated from Japan, followed by smaller numbers from the United States, Europe, and Canada. While geographic differences may reflect reporting patterns, the findings underscore the need for global vigilance.
Patients taking Tavneos should remain alert to early signs of liver injury. These symptoms may include:
If any of these symptoms occur, immediate medical evaluation is strongly recommended. Early detection can play a crucial role in preventing more severe outcomes.
In response to these findings, the FDA has issued updated guidance for clinicians managing patients on Tavneos. Key recommendations include:
Treatment should be discontinued promptly if significant abnormalities are detected. Specifically, clinicians are advised to stop Tavneos if liver enzymes such as ALT or AST exceed three times the upper limit of normal, or if alkaline phosphatase levels rise above twice the normal range.
Patients showing symptoms of cholestasis, such as jaundice or itching, should also have therapy stopped immediately. If liver function does not improve, referral to a liver specialist is recommended.
These findings highlight the importance of ongoing pharmacovigilance even after a drug has been approved. While Tavneos remains an important treatment option for a serious condition, its risk profile is now better understood.
Patients should not discontinue medication without consulting their healthcare provider. Instead, they should engage in open discussions about risks, benefits, and possible alternatives.
For clinicians, the new data reinforces the need for careful monitoring and patient education. Early intervention can reduce the likelihood of severe complications.
The identification of these safety concerns underscores the value of postmarketing surveillance systems such as the FDA Adverse Event Reporting System. These systems collect real world data that may not emerge during clinical trials, especially for rare adverse events.
In this case, postmarketing reports revealed a broader and more severe spectrum of liver injury than previously recognized. Continued monitoring will help determine whether additional regulatory actions are needed.
Both patients and healthcare professionals are encouraged to report side effects associated with Tavneos or any other medication. Reporting can be done through the FDA MedWatch program, which plays a vital role in identifying and assessing drug safety issues.
Increased reporting helps regulators detect patterns earlier and take appropriate action to protect public health.
The FDA has stated that it will continue to monitor cases of liver injury linked to avacopan and provide updates as more information becomes available. Future research may help clarify risk factors, identify vulnerable patient populations, and improve safety guidelines.
For now, awareness and proactive monitoring remain the most effective tools for minimizing risk.
Tavneos has offered hope for patients with ANCA associated vasculitis, but recent findings highlight important safety considerations. Serious liver injury, including rare and potentially fatal complications, has been reported in postmarketing data.
Patients should remain vigilant for symptoms and maintain regular communication with their healthcare providers. Clinicians should follow updated monitoring protocols and act quickly when abnormalities arise.
Balancing treatment benefits with potential risks is essential, and informed decision making is key to achieving the best possible outcomes.
U.S. Food and Drug Administration (FDA) Drug Safety Communication, March 31, 2026.
This article is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions regarding a medical condition or medication. Do not disregard professional medical advice or delay seeking it because of information presented here.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.